Verrica Pharmaceuticals · Nasdaq: VRCA · VP-102 (cantharidin)
VP-102 after the FDA's letters: the record, reconstructed.
3 FDA letters on NDA 212905, read alongside Verrica Pharmaceuticals' SEC filings. What changed after each FDA decision, in 9 questions answered from 16 source documents.
Quotes an FDA letterQuotes a company filingA line joins two questions whose answers quote the same passage. Hover a question to trace it.
FDA action or letterCompany filingHover a question to see which others share its evidence
Jul 2020
First Complete Response Letter
Aug 2020 – Feb 2021
Type A meeting and first resubmission
Sep 2021
Second Complete Response Letter
Sep – Nov 2021
Inspection closed and second resubmission
May 2022
Third Complete Response Letter
Jun – Sep 2022
Type A meeting and a new manufacturer
2020 – 2026
Across the record
Questions that span the whole record rather than one period
Cross-investigations involving Verrica Pharmaceuticals
Questions that connect Verrica Pharmaceuticals's record with other companies'.
- What happens after a second FDA Complete Response Letter?Divergent outcome · with Aldeyra Therapeutics · CorMedix · Outlook Therapeutics · Replimune
- What happens when an FDA letter turns on a contract manufacturer, not the drug?Shared concern · with CorMedix
- What did “no efficacy or safety issues” cover in these FDA letter announcements?Shared concern · with CorMedix · Replimune
Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →